JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Want to cut your energy bills? Here’s how five experts are doing it 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
DUBLIN, Ireland, Feb. 24, 2017 -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the fourth quarter and fiscal year 2016 on Tuesday, March 14, 2017. The Company has scheduled a conference call for that same day, Tuesday, March 14, 2017 at 11:00am ET (4:00pm GMT) to discuss the results of the quarter.
Interested parties can access the call by dialing:
| USA: | 1-844-861-5499 | |||||||||
| International: | 1-412-317-6581 | |||||||||
| Conference ID #: | 10102284 |
A simultaneous webcast of the call can be accessed at:
https://www.webcaster4.com/Webcast/Page/1135/19990
A replay of the call can be accessed until March 21, 2017 by dialing:
| USA: | 1-877-344-7529 | ||||||||||
| International: | 1-412-317-0088 | ||||||||||
| Conference ID #: | 10102284 | ||||||||||
The webcast of the call will be available for 30 days at:
https://www.webcaster4.com/Webcast/Page/1135/19990
Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: www.trinitybiotech.com.
Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.
Contact: Trinity Biotech plc Kevin Tansley (353)-1-2769800 E-mail: [email protected] Lytham Partners LLC Joe Diaz, Joe Dorame & Robert Blum 602-889-9700
